Knopp Biosciences Receives NIH HEAL Grant to Discover and Advance Non-Opioid Treatment for Chronic Pain
26.9.2019 18:00:00 EEST | Business Wire | Press release
Knopp Biosciences LLC today announced that the National Institutes of Health (NIH) has awarded the company a grant of as much as $8 million to utilize its novel Kv7 platform to discover and develop innovative non-opioid therapies for the treatment for chronic pain. The multi-year award comes through the NIH’s Helping to End Addiction Long-term, or the NIH HEAL Initiative, which aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose, and achieve long-term recovery from opioid addiction.
Knopp has developed a platform of molecules and assays directed to a non-narcotic biological target linked to neuropathic pain, or pain caused by damage to nerves. The target is a cellular membrane potassium channel called Kv7, which regulates the flow of electrically charged ions required to modulate the excitability of cells. Growing scientific evidence suggests that selectively activating key Kv7 channel subtypes can control nerve-cell hyperexcitability associated with chronic neuropathic pain.
“Knopp is excited to participate in the HEAL initiative and to discover novel solutions to this public health emergency,” said Michael Bozik, M.D., Chief Executive Officer of Knopp. “Our platform has already demonstrated the potential therapeutic benefit of targeted Kv7 channel activation in preclinical models of epilepsy, a disease, like pain, driven by abnormal firing of nerve cells. We are eager to extend Kv7 pharmacology to models of pain with the hope of developing effective oral medicines.”
Under the grant award, Knopp will identify targeted Kv7 activators for preclinical development with the goal of advancing effective treatments for chronic neuropathic pain, creating the potential for a new class of non-opioid medicines. Knopp’s research grant of as much as $8 million is based upon the attainment of milestones over five years.
Knopp’s award is one of 375 grant awards across 41 states made by the NIH in fiscal year 2019 to apply scientific solutions to reverse the national opioid crisis. “It’s clear that a multi-pronged scientific approach is needed to reduce the risks of opioids, accelerate development of effective non-opioid therapies for pain, and provide more flexible and effective options for treating addiction to opioids,” said NIH Director Francis S. Collins, M.D., Ph.D., who launched the initiative in early 2018. “This unprecedented investment in the NIH HEAL Initiative demonstrates the commitment to reversing this devastating crisis.”
Knopp’s lead Kv7 modulator, KB‐3061, is in preclinical development for KCNQ2 epileptic encephalopathy (KCNQ2-EE), a rare neonatal disease characterized by seizures beginning in the first days of life and by significant developmental delay in cognitive and motor function. As previously announced, KB-3061 has demonstrated potent seizure control and a wide therapeutic index in an in vivo model of epilepsy, and the restoration of mutated Kv7 channel function in cells transfected with gene variants that cause KCNQ2-EE.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopp’s preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy, non-opioid treatments for pain, and other CNS hyperexcitability disorders. Please visit www.knoppbio.com.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190926005597/en/
Contact information
Media inquiries:
James Heins
james.heins@icrinc.com
203-682-8251
Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial19.11.2026 15:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an alternative to – or even replace – gadolinium-based contrast agents (GBCAs), the current standard of care. This is because of their potential to address concerns with gadolinium-based contrast agents around retention in the body, supply chain resiliency, and the environment. This milestone comes seven months after the first patient was dosed at Mayo Clinic in April 2026, and builds on Phase 1 results showing the agent was well tolerated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119117575/en/ Representative pre- and post-mangaciclanol images in patients from the LUMINA Phase 2/3 trial
Ehime CATV expands public-sector connectivity in Japan with Adtran XGS-PON technology19.11.2026 15:00:00 EET | Press release
Adtran today announced that Ehime CATV has selected its XGS-PON technology to support a new broadband network for public schools and local government offices in Ehime Prefecture, Japan. The deployment will provide 10Gbit/s connectivity to more than 100 public-sector sites, supporting digital learning, cloud-based applications and everyday online services for students, teachers and municipal users. With its compact footprint and flexible expansion model, Adtran’s access technology will help Ehime CATV transition beyond legacy EPON infrastructure to ITU-based XGS-PON. The upgrade will also support a more diversified supplier strategy, helping mitigate geopolitical supply chain risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119028160/en/ Adtran’s XGS-PON technology is helping Ehime CATV develop a new broadband network for public schools and local government offices. “Supporting the communities we serve has always been
Stronghold Joins the World Economic Forum's New Champions Community19.11.2026 15:00:00 EET | Press release
Stronghold, a fintech infrastructure company, today announced that it has joined the World Economic Forum’s New Champions Community. The New Champions Community is the World Economic Forum’s global network of mission-driven companies, drawn from more than 40 countries and 20 industries. Its work centers on how businesses anticipate change, adapt to disruption and build resilience. Stronghold provides payments infrastructure for merchants and the banks that serve them. The company carries the compliance work that allows banks to serve licensed businesses they would otherwise decline, and makes that work visible to every party in a transaction. That is where resilience gets tested: whether money keeps moving when a market shifts, a rule changes or a bank revisits its risk appetite. “The New Champions Community reflects the values we care about: trust, compliance, and financial innovation,” said Tammy Camp, CEO of Stronghold. “Joining gives us the chance to learn from leaders in industrie
Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 14:05:00 EET | Press release
At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119101038/en/ Ant International at the Singapore Fintech Festival 2026 YP highlighted three critical angles to tackle the future financial system: How should settlement infrastructure evolve in the AI + blockchain era to establish new game rules? How to build cross-rail, cross-modal trust for the agentic economy? How to mainstream inclusion into AI design to close the accessibility gap for SMEs? The Missing Debate: Rewiring settlement infrastructure The four-party payment model — issuer, acquirer, network, regulator — has served as a mature bedrock for traditional economy. However, would we still need the acqu
NIQ Appoints Danny Lange and Chris Tung to Board of Directors19.11.2026 13:45:00 EET | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that Danny Lange and Chris Tung have been appointed to its Board of Directors, effective Nov. 18, 2026. Lange brings more than three decades of technology leadership, including senior roles building and scaling artificial intelligence and machine learning capabilities at Google, Unity, Uber, Amazon and Microsoft. Tung brings extensive operating, consumer and digital commerce experience across Greater China and Asia Pacific through leadership roles at Shangri-La Asia, Alibaba, PepsiCo, L’Oréal and other global businesses. Together, their experience strengthens the Board’s perspective as NIQ advances its AI strategy and expands its impact across global markets. “Danny and Chris bring expertise that directly aligns with where NIQ is going,” said Jim Peck, Executive Chairman and Chief Executive Officer of NIQ. “Danny has spent his career building AI and machine learning capabilities at scale. Chris brings deep
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
